<DOC>
	<DOCNO>NCT02279758</DOCNO>
	<brief_summary>Neuroendocrine tumor rare recent data show relevant increase incidence . The Mammalian Target Rapamycin ( mTOR ) , one important area research , demonstrate therapeutic target tumor . The metformin demonstrate preclinical study antineoplastic action inhibit mTOR pathway , may alternative treatment disease . Eligible patient study metastatic gastroenteropancreatic neuroendocrine tumor well differentiate ( grade 1 grade 2 ) treat metformin 850 mg every 12 hour , cycle consist 30 day . After 180 day treatment efficacy metformin control disease progression evaluate . As secondary outcome investigator check patient adherence treatment , control patient symptom function neuroendocrine tumor , disease free survival . Also perform analysis immunohistochemical expression mTOR pathway proteins patient .</brief_summary>
	<brief_title>A Pilot Study Metformin Treatment Patients With Well-differentiated Neuroendocrine Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Metastatic welldifferentiated neuroendocrine tumor grade 1 2 histological confirmation ; Performance status accord Eastern Cooperative Oncology Group ( ECOG ) 0 2 ; Able take pill ; Age â‰¥ 16 year ; Ability Provide Written Informed Consent ; Adequate organ function ; Patient control severe hormonal syndrome ; Diabetic patient metformin treatment , receive treatment metformin within 3 month ; Patient hypersensitivity biguanides , kidney liver failure , condition predispose lactic acidosis ; History severe clinical psychiatric illness , would prevent participation study clinical judgment ; Patients participate protocol experimental drug ; Patients kind active infection ; Patients receive chemotherapy within 3 week ; Patients pregnant lactating ; Diabetic patient require high dose metformin 850mg x 2 daily ;</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Neuroendocrine Tumors</keyword>
	<keyword>The Mammalian Target Rapamycin ( mTOR )</keyword>
	<keyword>metformin</keyword>
</DOC>